A5037630607- Facial Rejuvenation and Surgery Techniques
- Dermatologic Treatments and Research
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Body Image and Dysmorphia Studies
- Health Systems, Economic Evaluations, Quality of Life
- Hair Growth and Disorders
- Body Contouring and Surgery
- Evolutionary Psychology and Human Behavior
- Botulinum Toxin and Related Neurological Disorders
- Pharmaceutical studies and practices
- Vascular Tumors and Angiosarcomas
- Sympathectomy and Hyperhidrosis Treatments
- Rheumatoid Arthritis Research and Therapies
- Orthodontics and Dentofacial Orthopedics
- Transportation and Mobility Innovations
- Skin Protection and Aging
- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Nail Diseases and Treatments
- Parathyroid Disorders and Treatments
- Facial Nerve Paralysis Treatment and Research
- Autoimmune and Inflammatory Disorders Research
- Biosimilars and Bioanalytical Methods
- Digital Imaging in Medicine
Baylor College of Medicine
1997-2022
Ospedale Bellaria
2021
Allergan (Ireland)
2016
C-reactive protein (CRP), an inflammation biomarker, indicates cardiovascular risk and is elevated in psoriasis. The effect of etanercept on CRP psoriasis has not been previously examined.The primary objective was to examine the levels from baseline week 12 compared with placebo. Secondary objectives included assessment relationships between body mass index (BMI), statin drug use, Psoriasis Area Severity Index (PASI) scores.A retrospective analysis conducted patients who participated a...
Patients with psoriasis value rapid and complete skin clearance. No head‐to‐head studies have focused on early responses to interleukin (IL)‐17 vs. IL‐23 inhibitors. To compare clearance by the IL‐17A inhibitor ixekizumab IL‐23p19 guselkumab. IXORA‐R, a 24‐week, randomized, double‐blinded study, enrolled adults moderate‐to‐severe plaque [static Physician's Global Assessment of Disease (sPGA) score ≥ 3, Psoriasis Area Severity Index (PASI) 12, 10% body surface area]. were randomized (1 : 1)...
BackgroundOBSERVE-5 was a 5-year Food and Drug Administration–mandated surveillance registry of patients with psoriasis.ObjectiveWe sought to assess long-term etanercept safety effectiveness.MethodsPatients moderate severe psoriasis enrolled; single baseline dose required. Key outcome measures included serious adverse events, infectious events medical interest, psoriasis-affected body surface area, physician global assessment score, Dermatology Life Quality Index score. Safety outcomes were...
Individuals seeking aesthetic treatment have concerns regarding multiple facial areas. Assess the impact and satisfaction achieved with a multimodal approach to using combination of minimally invasive treatments. Prospective, multicenter, rater-blinded, 4-month HARMONY study evaluated patient fillers (VYC-20L, HYC-24L, HYC-24L+), onabotulinumtoxinA, bimatoprost. Males females aged 35 65 years received on-label, staged fillers, as needed per investigator assessment, on day 1, touch ups...
Abstract Background The impact of facial aesthetic treatments not only enhances physical appearance but also psychological well-being. Accordingly, patient-reported outcomes are increasingly utilized as an important measure treatment success. Observer-reported a relevant yet often overlooked benefit. Objectives authors aimed to evaluate the panfacial on perception individual in variety social contexts. Methods A total 2000 men and women (aged 18-65 years) participated online study designed...
BACKGROUND The HARMONY study is the first clinical trial to assess impact of a global approach facial rejuvenation with several minimally invasive modalities, using patient-reported outcome measures. OBJECTIVE Provide details this treatment and describe investigators' experiences recommendations based on study. METHODS This multicenter, 4-month evaluated subject satisfaction psychological combined VYC-20L (Juvéderm Voluma XC), HYC-24L Ultra HYC-24L+ Plus onabotulinumtoxinA (Botox),...
Abstract Background A global approach to facial rejuvenation involves multiple treatment modalities. Objectives The aim of this study was evaluate the impact multimodal aesthetic on self-reported psychological and social outcomes. Methods HARMONY, a prospective, multicenter, 4-month study, enrolled patients aged 35 65 years receive on-label with combination hyaluronic fillers (VYC-20L, HYC-24L, and/or HYC-24L+), onabotulinumtoxinA, bimatoprost. Fillers were injected Day 1, touch-ups...
Importance Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in nodules adults moderate to severe PN previous 16-week phase 3 study (OLYMPIA 2). Objective To assess the efficacy occurrence of adverse events treated nemolizumab vs those receiving placebo. Design, Setting, Participants OLYMPIA 1 was multicenter, placebo-controlled, randomized clinical trial,...
Microneedling and soft-tissue filler injections have been used independently to improve acne scarring. The effectiveness of a combined approach using microneedling followed by polymethylmethacrylate (PMMA)-collagen gel has not carefully studied.The goal this study was assess the safety alone versus injection PMMA-collagen for correction atrophic facial scars.We conducted multicenter, open-label, randomized, prospective on subjects with distensible scars in face determine whether is superior...
Etanercept is approved for the treatment of chronic moderate to severe plaque psoriasis in adults.We sought evaluate long-term safety etanercept a real-world clinical setting. Assessment efficacy was secondary objective.OBSERVE-5 5-year observational registry initiated May 2006 at multiple sites United States and Canada. Data collection includes number serious adverse events, infectious prespecified events medical interest. Efficacy data include body surface area assessments, physician...
Abstract Background Psoriasis treatment can lower levels of the inflammatory biomarker C‐reactive protein ( CRP ). Objective Evaluate changes in patients with chronic plaque psoriasis who switched to adalimumab following suboptimal response previous therapies. Methods was measured at screening and after 16 weeks discontinuation therapies: etanercept (substudy E; n = 77), methotrexate M; 38) or narrow‐band ultraviolet B phototherapy P; 27). Associations baseline characteristics efficacy...
BACKGROUND Submental fat (SMF) can negatively affect perceptions of health and attractiveness. The Condition Fullness Treatment Outcomes Registry (CONTOUR) was designed to understand SMF treatment in clinical practice. OBJECTIVE To report efficacy, characteristics, safety associated with real-world use ATX-101 (deoxycholic acid injection). METHODS CONTOUR enrolled adults considering for reduction. ATX-101–treated patients who completed the end-of-treatment questionnaire were divided into...
Submental fat can be reduced with ATX-101 (deoxycholic acid injection), a customizable and minimally invasive alternative to liposuction. In the years since its approval, treatment patterns of have evolved.A panel experienced physicians from United States gathered generate best practices for use in submental contouring.The expert provided their insights on appropriate patient selection, managing expectations outcomes, adverse events, guidance administration optimal outcomes are presented...
Abstract Any practitioner trained in using cosmetic botulinum toxin type A for on‐label and off‐label indications must stay informed of the possible complications from treatments. Though prevention is ideal, management adverse events, when they occur, integral a positive patient outcome. Major long‐term treatment are rarely observed because agent eventually metabolizes after 3–4 months. As such, minor more commonly may be problematic short‐term. These seen can organized into three main...
Background OBSERVE-5 is collecting safety data from real-world use of etanercept in the treatment psoriasis per a post-marketing commitment U.S. Food and Drug Administration. Methods This phase IV prospective, multicenter, 5-year observational registry was designed to enroll patients with plaque for whom indicated. Patients receive standard medical care can discontinue therapy at any time following receipt baseline dose. Visits occur least twice yearly; follow-up will be up 5 years....
Background: HA RC is a soft and flexible hyaluronic acid filler containing lidocaine, manufactured using XpresHAn ® technology, restoring natural-looking volume contours.Objectives: To evaluate safety effectiveness of for cheek augmentation correction midface contour deficiencies compared to control product JV (hereafter referred as Control).Primary objective was demonstrate non-inferiority the Control, by blinded evaluation change from baseline in fullness 12 weeks after last injection, 4...
Background: A firming and toning cosmetic body lotion (FTB) was developed to target key pathways relevant skin health rejuvenation that may complement the improvements observed after noninvasive contouring (NIBC). pilot study explored efficacy tolerability of FTB as an adjunct cryolipolysis.
Abstract Not Available Disclosures: Study supported by Allergan.
Abstract not available.